TCMD TACTILE SYSTEMS TECHNOLOGY INC
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1027838 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.4%
TTM net income YoY31.1%
TTM EPS YoY35.5%
Revenue 3-yr CAGR9.6%
Net income 3-yr CAGR-1.5%
Margins
Gross margin77.0%
Operating margin9.4%
Net margin6.7%
FCF margin8.1%
EBITDA margin11.4%
Returns
ROE11.0%
ROA8.7%
ROIC (approx.)15.3%
Asset turnover1.29x
Leverage & solvency
Liabilities / assets22.0%
Debt / equity0.00x
Current ratio3.51x
Interest coverage431.51x
Cash quality & payout
Operating cash flow / net income1.35x
Accruals ratio-3.0%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $329.52M | $292.98M |
| Cost of revenue | $79.38M | $76.30M |
| Gross profit | $250.15M | $216.69M |
| R&D expense | $8.48M | $8.83M |
| SG&A expense | $88.70M | $71.14M |
| Operating income | $29.28M | $22.18M |
| Interest expense | $1.04M | $2.08M |
| Pretax income | $31.34M | $23.49M |
| Income tax | $12.25M | $6.53M |
| Net income | $19.09M | $16.96M |
| EBITDA | $35.92M | $28.97M |
| EPS (basic) | 0.83 | 0.71 |
| EPS (diluted) | 0.82 | 0.70 |
| Weighted avg. shares (diluted) | 23.30M | 24.14M |
| Balance sheet | ||
| Cash & equivalents | $83.45M | $94.37M |
| Receivables | $43.88M | $44.94M |
| Inventory | $14.03M | $18.67M |
| Current assets | $165.17M | $177.56M |
| PP&E, net | $5.12M | $5.60M |
| Goodwill | $31.06M | $31.06M |
| Intangibles | $39.17M | $42.79M |
| Total assets | $273.94M | $297.92M |
| Current liabilities | $40.96M | $40.70M |
| Long-term debt | $0 | — |
| Total debt | $0 | — |
| Total liabilities | $55.04M | $81.33M |
| Shareholders' equity | $218.90M | $216.60M |
| Net debt | -$83.45M | — |
| Shares outstanding | 22.44M | 23.88M |
| Cash flow statement | ||
| Operating cash flow | $42.81M | $40.66M |
| Capital expenditure | $2.38M | $2.39M |
| Free cash flow | $40.43M | $38.26M |
| Investing cash flow | -$2.54M | -$2.50M |
| Financing cash flow | -$51.20M | -$4.82M |
| Depreciation & amortization | $6.64M | $6.79M |
| Stock-based compensation | $8.36M | $7.82M |
| Share buybacks | $26.56M | $3.51M |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.